Purpura thrombotique thrombocytopénique réfractaire révélant un cancer de l’épiglotte

Baudin, Florent; Guillot, Pascale; Bedock, B.; Blanc, P.

doi:10.1016/j.annfar.2012.01.035

Annales Françaises d'Anesthésie et de Réanimation

2012

DOI: 10.1016/j.annfar.2012.01.035

|View full text |Cite

Purpura thrombotique thrombocytopénique réfractaire révélant un cancer de l’épiglotte

Florent Baudin

Pascale Guillot²,

B. Bedock³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2020

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the evasive clinical differences between TTP and other kinds of secondary TMA in solid tumor patients, [ 2 ] we recommend the test for ADAMTS13 activity and the inhibitor level for the diagnosis of acquired TTP. Similar to our patient, an epiglottic squamous cell carcinoma patient was also diagnosed as TTP (confirmed by ADAMTS13 activity) before tumor treatment, [ 3 ] indicating the role of solid tumor instead of drugs or surgery, the two reported causes of TTP, [ 1 , 2 ] in the pathogenesis. The mechanism of tumor-associated TTP remains elusive.…”

supporting

confidence: 81%

Cholangiocarcinoma presenting with acquired thrombotic thrombocytopenic purpura confirmed by positive autoantibodies of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13

Wang

et al. 2020

Chinese Medical Journal

View full text Add to dashboard Cite

supporting

confidence: 81%

Cholangiocarcinoma presenting with acquired thrombotic thrombocytopenic purpura confirmed by positive autoantibodies of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13

Wang

et al. 2020

Chinese Medical Journal

View full text Add to dashboard Cite

May the change of platelet to lymphocyte ratio be a prognostic factor for T3-T4 laryngeal squamous cell carcinoma: A retrospective study

Zhong

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

BackgroundMany blood markers have been shown to predict the recurrence and survival of various malignancies, but the effects of surgery on the body's inflammatory levels may cause changes in these inflammatory markers. Therefore, in this study, we assessed the relationship between changes in platelet to lymphocyte ratio (PLR) and survival and recurrence in patients with T3-T4 laryngeal squamous cell carcinoma (LSCC).MethodsData of patients with T3-T4 HSCC were reviewed. Continuous variables were expressed as mean ± SD and were compared using t test or Mann-Whitney U test. The covariate distributions were compared by Chi-square test. Survival curve was estimated by Kaplan-Meier analysis, and Log-Rank test were performed to estimate the survival curve and significance of the difference in survival distribution between groups, respectively. The prognostic value was uncovered by univariate and multivariate Cox hazards analysis.ResultsThe 413 consecutive patients with LSCC were reviewed. Of these, 362 patients who met the criteria were selected, multi-factor analysis found that pathological T classification(hazard ratio [HR] = 1.878; 95% confidence interval [CI] = 1.342–3.023; P<0.001), pathological N classification (HR = 1.212; 95% CI = 0.867–2.125; P< 0.001) and change of PLR (HR = 2.158; 95% CI = 1.332–2.889; P = 0.004) associated with postoperative recurrence of T3-T4 LSCC. In addition, the pathological T classification (HR = 1.901; 95% CI = 1.255–2.999; P<0.001), pathological N classification (HR = 1.244; 95% CI = 0.810–2.212; P<0.001) and change of PLR (HR = 2.011; 95% CI = 1.354–2.753; P = 0.001) associated with postoperative survival in patients with T3-T4 LSCC.ConclusionsResults demonstrate that change in PLR may serve as a useful prognostic predictor for patients with T3-T4 LSCC.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Purpura thrombotique thrombocytopénique réfractaire révélant un cancer de l’épiglotte

Cited by 2 publications

References 20 publications

Cholangiocarcinoma presenting with acquired thrombotic thrombocytopenic purpura confirmed by positive autoantibodies of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13

Cholangiocarcinoma presenting with acquired thrombotic thrombocytopenic purpura confirmed by positive autoantibodies of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13

May the change of platelet to lymphocyte ratio be a prognostic factor for T3-T4 laryngeal squamous cell carcinoma: A retrospective study

Contact Info

Product

Resources

About